PureTech Health (NASDAQ:PRTC) Shares Gap Up – Should You Buy?

PureTech Health plc (NASDAQ:PRTC) shares gapped up before the market opened on Monday . The stock had previously closed at $20.35, but opened at $22.73. PureTech Health shares last traded at $23.12, with a volume of 11,986 shares.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on PRTC shares. Leerink Partners started coverage on shares of PureTech Health in a research report on Monday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. Leerink Partnrs raised PureTech Health to a “strong-buy” rating in a report on Monday, September 9th.

PureTech Health Trading Up 8.8 %

The company has a fifty day moving average of $21.18 and a two-hundred day moving average of $22.54.

Institutional Investors Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new stake in PureTech Health plc (NASDAQ:PRTC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.